Prostatype Genomics AB (FRA:PGO0) PS Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PGO0 Prostatype Genomics AB FRA:PGO0
23 GF Score
Price €0.01
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Prostatype Genomics AB's share price is €0.0068. Prostatype Genomics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00. Hence, Prostatype Genomics AB's PS Ratio for today is .

Good Sign:

Prostatype Genomics AB stock PS Ratio (=14) is close to 2-year low of 14.

The historical rank and industry rank for Prostatype Genomics AB's PS Ratio or its related term are showing as below:

FRA:PGO0' s PS Ratio Range Over the Past 10 Years
Min: 1.24   Med: 798.91   Max: 14082.41
Current: 11.57

During the past 7 years, Prostatype Genomics AB's highest PS Ratio was 14082.41. The lowest was 1.24. And the median was 798.91.

FRA:PGO0's PS Ratio is ranked worse than
85.43% of 199 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.73 vs FRA:PGO0: 11.57

Prostatype Genomics AB's Revenue per Sharefor the six months ended in Dec. 2025 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.

Warning Sign:

Prostatype Genomics AB revenue per share has been in decline over the past 3 years.

During the past 3 years, the average Revenue per Share Growth Rate was -87.60% per year.

During the past 7 years, Prostatype Genomics AB's highest 3-Year average Revenue per Share Growth Rate was 115.70% per year. The lowest was -87.60% per year. And the median was -73.70% per year.

Back to Basics: PS Ratio


Prostatype Genomics AB  (FRA:PGO0) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Prostatype Genomics AB PS Ratio Related Terms


Prostatype Genomics AB PS Ratio Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB PS Ratio Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial 13,266.26 12.12 3,066.52 0.00 16.31

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,066.52 0.00 0.00 0.00 16.31

FRA:PGO0 vs TMO, DHR, IDXX: PS Ratio Comparison

For the Diagnostics & Research subindustry, Prostatype Genomics AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's PS Ratio falls into.


FRA:PGO0
23GF Score
Prostatype Genomics AB FRA:PGO0
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Prostatype Genomics AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0068/0
=

Prostatype Genomics AB's Share Price of today is €0.0068.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Prostatype Genomics AB Business Description

Other Exchanges PROGEN:Sweden
Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score

Get the complete analysis for FRA:PGO0

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price